Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done
Adoption of single-fraction lung stereotactic body radiation therapy (SBRT) for patients with medically inoperable early stage non-small-cell lung cancer (NSCLC) or oligometastatic lung disease, even during the coronavirus disease 2019 (COVID-19) pandemic, was limited despite encouraging phase II tr...
Gespeichert in:
| Veröffentlicht in: | Cancers 2022-02, Vol.14 (3), p.790 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 790 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Bartl, Austin J Mahoney, Mary Hennon, Mark W Yendamuri, Sai Videtic, Gregory M M Stephans, Kevin L Siva, Shankar Farrugia, Mark K Ma, Sung Jun Singh, Anurag K |
| description | Adoption of single-fraction lung stereotactic body radiation therapy (SBRT) for patients with medically inoperable early stage non-small-cell lung cancer (NSCLC) or oligometastatic lung disease, even during the coronavirus disease 2019 (COVID-19) pandemic, was limited despite encouraging phase II trial results. Barriers to using single-fraction SBRT may include lack of familiarity with the regimen and lack of clarity about the expected toxicity. To address these concerns, we performed a systematic review of prospective literature on single-fraction SBRT for definitive treatment of early stage and oligometastatic lung cancer. A PubMed search of prospective studies in English on single-fraction lung SBRT was conducted. A systematic review was performed of the studies that reported clinical outcomes of single-fraction SBRT in the treatment of early stage non-small-cell lung cancer and lung oligometastases. The current prospective literature including nine trials supports the use of single-fraction SBRT in the definitive treatment of early stage peripheral NSCLC and lung oligometastases. Most studies cite local control rates of >90%, mild toxicity profiles, and favorable survival outcomes. Most toxicities reported were grade 1-2, with grade ≥3 toxicity in 0-17% of patients. Prospective trial results suggest potential consideration of utilizing single-fraction SBRT beyond the COVID-19 pandemic. |
| doi_str_mv | 10.3390/cancers14030790 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8834253</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2627536065</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-b1d70de84ed59370cdb15668a09d12f269aa5382b25841353396da1070f0d0f93</originalsourceid><addsrcrecordid>eNpdkk1r3DAQhk1pacI2596KoJde3OjDkuweCu02H4WlC9mUHo1WGjsKtrSR7A3-Z_150e6mIY0QSMM88zIzvFn2nuDPjFX4VCunIURSYIZlhV9lxxRLmgtRFa-f_Y-ykxhvcTqMESnk2-yIccIrzOVx9nc1xQF6NViNrmBr4R75Bq2sazvIz4PSg_UOrQYI4IddpNF3byZ0pYxV-9z1DQS1mVDjAzpToZsSrVpAv7zLV73qunwOXYcWo2vRfN8xUs4c4mVnW9_DoGK6EL-gS3-PBp8U_Ab98SFMqZED7reAlg72wQ_v4F32plFdhJPHd5b9Pj-7nl_mi-XFz_m3Ra4LSoZ8TYzEBsoCDK-YxNqsCReiVLgyhDZUVEpxVtI15WVBGE-LFUYRLHGDDW4qNsu-HnQ347oHo8ENQXX1Jthehan2ytb_Z5y9qVu_rcuSFTTpzbJPjwLB340Qh7q3UaeVKAd-jDUVtMKCUiET-vEFeuvH4NJ4O0pyJrDgiTo9UDr4GAM0T80QXO-MUb8wRqr48HyGJ_6fDdgD0wa2_g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627536065</pqid></control><display><type>article</type><title>Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Bartl, Austin J ; Mahoney, Mary ; Hennon, Mark W ; Yendamuri, Sai ; Videtic, Gregory M M ; Stephans, Kevin L ; Siva, Shankar ; Farrugia, Mark K ; Ma, Sung Jun ; Singh, Anurag K</creator><creatorcontrib>Bartl, Austin J ; Mahoney, Mary ; Hennon, Mark W ; Yendamuri, Sai ; Videtic, Gregory M M ; Stephans, Kevin L ; Siva, Shankar ; Farrugia, Mark K ; Ma, Sung Jun ; Singh, Anurag K</creatorcontrib><description>Adoption of single-fraction lung stereotactic body radiation therapy (SBRT) for patients with medically inoperable early stage non-small-cell lung cancer (NSCLC) or oligometastatic lung disease, even during the coronavirus disease 2019 (COVID-19) pandemic, was limited despite encouraging phase II trial results. Barriers to using single-fraction SBRT may include lack of familiarity with the regimen and lack of clarity about the expected toxicity. To address these concerns, we performed a systematic review of prospective literature on single-fraction SBRT for definitive treatment of early stage and oligometastatic lung cancer. A PubMed search of prospective studies in English on single-fraction lung SBRT was conducted. A systematic review was performed of the studies that reported clinical outcomes of single-fraction SBRT in the treatment of early stage non-small-cell lung cancer and lung oligometastases. The current prospective literature including nine trials supports the use of single-fraction SBRT in the definitive treatment of early stage peripheral NSCLC and lung oligometastases. Most studies cite local control rates of >90%, mild toxicity profiles, and favorable survival outcomes. Most toxicities reported were grade 1-2, with grade ≥3 toxicity in 0-17% of patients. Prospective trial results suggest potential consideration of utilizing single-fraction SBRT beyond the COVID-19 pandemic.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14030790</identifier><identifier>PMID: 35159057</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Cancer therapies ; Chemotherapy ; Clinical trials ; Coronaviruses ; COVID-19 ; Failure ; Familiarity ; Lung cancer ; Lung diseases ; Metastasis ; Non-small cell lung carcinoma ; Oncology ; Pandemics ; Patients ; Quality of life ; Radiation therapy ; Small cell lung carcinoma ; Systematic Review ; Toxicity ; Tumors</subject><ispartof>Cancers, 2022-02, Vol.14 (3), p.790</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-b1d70de84ed59370cdb15668a09d12f269aa5382b25841353396da1070f0d0f93</citedby><cites>FETCH-LOGICAL-c421t-b1d70de84ed59370cdb15668a09d12f269aa5382b25841353396da1070f0d0f93</cites><orcidid>0000-0003-2840-0658 ; 0000-0002-1857-9423 ; 0000-0002-0261-0334 ; 0000-0002-0838-3996</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834253/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834253/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35159057$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bartl, Austin J</creatorcontrib><creatorcontrib>Mahoney, Mary</creatorcontrib><creatorcontrib>Hennon, Mark W</creatorcontrib><creatorcontrib>Yendamuri, Sai</creatorcontrib><creatorcontrib>Videtic, Gregory M M</creatorcontrib><creatorcontrib>Stephans, Kevin L</creatorcontrib><creatorcontrib>Siva, Shankar</creatorcontrib><creatorcontrib>Farrugia, Mark K</creatorcontrib><creatorcontrib>Ma, Sung Jun</creatorcontrib><creatorcontrib>Singh, Anurag K</creatorcontrib><title>Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Adoption of single-fraction lung stereotactic body radiation therapy (SBRT) for patients with medically inoperable early stage non-small-cell lung cancer (NSCLC) or oligometastatic lung disease, even during the coronavirus disease 2019 (COVID-19) pandemic, was limited despite encouraging phase II trial results. Barriers to using single-fraction SBRT may include lack of familiarity with the regimen and lack of clarity about the expected toxicity. To address these concerns, we performed a systematic review of prospective literature on single-fraction SBRT for definitive treatment of early stage and oligometastatic lung cancer. A PubMed search of prospective studies in English on single-fraction lung SBRT was conducted. A systematic review was performed of the studies that reported clinical outcomes of single-fraction SBRT in the treatment of early stage non-small-cell lung cancer and lung oligometastases. The current prospective literature including nine trials supports the use of single-fraction SBRT in the definitive treatment of early stage peripheral NSCLC and lung oligometastases. Most studies cite local control rates of >90%, mild toxicity profiles, and favorable survival outcomes. Most toxicities reported were grade 1-2, with grade ≥3 toxicity in 0-17% of patients. Prospective trial results suggest potential consideration of utilizing single-fraction SBRT beyond the COVID-19 pandemic.</description><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Failure</subject><subject>Familiarity</subject><subject>Lung cancer</subject><subject>Lung diseases</subject><subject>Metastasis</subject><subject>Non-small cell lung carcinoma</subject><subject>Oncology</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Quality of life</subject><subject>Radiation therapy</subject><subject>Small cell lung carcinoma</subject><subject>Systematic Review</subject><subject>Toxicity</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkk1r3DAQhk1pacI2596KoJde3OjDkuweCu02H4WlC9mUHo1WGjsKtrSR7A3-Z_150e6mIY0QSMM88zIzvFn2nuDPjFX4VCunIURSYIZlhV9lxxRLmgtRFa-f_Y-ykxhvcTqMESnk2-yIccIrzOVx9nc1xQF6NViNrmBr4R75Bq2sazvIz4PSg_UOrQYI4IddpNF3byZ0pYxV-9z1DQS1mVDjAzpToZsSrVpAv7zLV73qunwOXYcWo2vRfN8xUs4c4mVnW9_DoGK6EL-gS3-PBp8U_Ab98SFMqZED7reAlg72wQ_v4F32plFdhJPHd5b9Pj-7nl_mi-XFz_m3Ra4LSoZ8TYzEBsoCDK-YxNqsCReiVLgyhDZUVEpxVtI15WVBGE-LFUYRLHGDDW4qNsu-HnQ347oHo8ENQXX1Jthehan2ytb_Z5y9qVu_rcuSFTTpzbJPjwLB340Qh7q3UaeVKAd-jDUVtMKCUiET-vEFeuvH4NJ4O0pyJrDgiTo9UDr4GAM0T80QXO-MUb8wRqr48HyGJ_6fDdgD0wa2_g</recordid><startdate>20220203</startdate><enddate>20220203</enddate><creator>Bartl, Austin J</creator><creator>Mahoney, Mary</creator><creator>Hennon, Mark W</creator><creator>Yendamuri, Sai</creator><creator>Videtic, Gregory M M</creator><creator>Stephans, Kevin L</creator><creator>Siva, Shankar</creator><creator>Farrugia, Mark K</creator><creator>Ma, Sung Jun</creator><creator>Singh, Anurag K</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2840-0658</orcidid><orcidid>https://orcid.org/0000-0002-1857-9423</orcidid><orcidid>https://orcid.org/0000-0002-0261-0334</orcidid><orcidid>https://orcid.org/0000-0002-0838-3996</orcidid></search><sort><creationdate>20220203</creationdate><title>Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done</title><author>Bartl, Austin J ; Mahoney, Mary ; Hennon, Mark W ; Yendamuri, Sai ; Videtic, Gregory M M ; Stephans, Kevin L ; Siva, Shankar ; Farrugia, Mark K ; Ma, Sung Jun ; Singh, Anurag K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-b1d70de84ed59370cdb15668a09d12f269aa5382b25841353396da1070f0d0f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Failure</topic><topic>Familiarity</topic><topic>Lung cancer</topic><topic>Lung diseases</topic><topic>Metastasis</topic><topic>Non-small cell lung carcinoma</topic><topic>Oncology</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Quality of life</topic><topic>Radiation therapy</topic><topic>Small cell lung carcinoma</topic><topic>Systematic Review</topic><topic>Toxicity</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bartl, Austin J</creatorcontrib><creatorcontrib>Mahoney, Mary</creatorcontrib><creatorcontrib>Hennon, Mark W</creatorcontrib><creatorcontrib>Yendamuri, Sai</creatorcontrib><creatorcontrib>Videtic, Gregory M M</creatorcontrib><creatorcontrib>Stephans, Kevin L</creatorcontrib><creatorcontrib>Siva, Shankar</creatorcontrib><creatorcontrib>Farrugia, Mark K</creatorcontrib><creatorcontrib>Ma, Sung Jun</creatorcontrib><creatorcontrib>Singh, Anurag K</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bartl, Austin J</au><au>Mahoney, Mary</au><au>Hennon, Mark W</au><au>Yendamuri, Sai</au><au>Videtic, Gregory M M</au><au>Stephans, Kevin L</au><au>Siva, Shankar</au><au>Farrugia, Mark K</au><au>Ma, Sung Jun</au><au>Singh, Anurag K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2022-02-03</date><risdate>2022</risdate><volume>14</volume><issue>3</issue><spage>790</spage><pages>790-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Adoption of single-fraction lung stereotactic body radiation therapy (SBRT) for patients with medically inoperable early stage non-small-cell lung cancer (NSCLC) or oligometastatic lung disease, even during the coronavirus disease 2019 (COVID-19) pandemic, was limited despite encouraging phase II trial results. Barriers to using single-fraction SBRT may include lack of familiarity with the regimen and lack of clarity about the expected toxicity. To address these concerns, we performed a systematic review of prospective literature on single-fraction SBRT for definitive treatment of early stage and oligometastatic lung cancer. A PubMed search of prospective studies in English on single-fraction lung SBRT was conducted. A systematic review was performed of the studies that reported clinical outcomes of single-fraction SBRT in the treatment of early stage non-small-cell lung cancer and lung oligometastases. The current prospective literature including nine trials supports the use of single-fraction SBRT in the definitive treatment of early stage peripheral NSCLC and lung oligometastases. Most studies cite local control rates of >90%, mild toxicity profiles, and favorable survival outcomes. Most toxicities reported were grade 1-2, with grade ≥3 toxicity in 0-17% of patients. Prospective trial results suggest potential consideration of utilizing single-fraction SBRT beyond the COVID-19 pandemic.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35159057</pmid><doi>10.3390/cancers14030790</doi><orcidid>https://orcid.org/0000-0003-2840-0658</orcidid><orcidid>https://orcid.org/0000-0002-1857-9423</orcidid><orcidid>https://orcid.org/0000-0002-0261-0334</orcidid><orcidid>https://orcid.org/0000-0002-0838-3996</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2022-02, Vol.14 (3), p.790 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8834253 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Cancer therapies Chemotherapy Clinical trials Coronaviruses COVID-19 Failure Familiarity Lung cancer Lung diseases Metastasis Non-small cell lung carcinoma Oncology Pandemics Patients Quality of life Radiation therapy Small cell lung carcinoma Systematic Review Toxicity Tumors |
| title | Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T10%3A01%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Systematic%20Review%20of%20Single-Fraction%20Stereotactic%20Body%20Radiation%20Therapy%20for%20Early%20Stage%20Non-Small-Cell%20Lung%20Cancer%20and%20Lung%20Oligometastases:%20How%20to%20Stop%20Worrying%20and%20Love%20One%20and%20Done&rft.jtitle=Cancers&rft.au=Bartl,%20Austin%20J&rft.date=2022-02-03&rft.volume=14&rft.issue=3&rft.spage=790&rft.pages=790-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14030790&rft_dat=%3Cproquest_pubme%3E2627536065%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627536065&rft_id=info:pmid/35159057&rfr_iscdi=true |